Yungjin Pharm Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top 15 shareholders own 54.63% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
52.5%	KT&G Corporation	95,928,655	₩202.9b	0%	no data
1.57%	The Vanguard Group, Inc.	2,866,797	₩6.1b	0%	no data
0.26%	Dimensional Fund Advisors LP	474,824	₩1.0b	11.2%	no data
0.13%	Mirae Asset Global Investments Co., Ltd.	229,045	₩484.4m	27.8%	no data
0.082%	Samsung Asset Management Company, Ltd.	150,839	₩319.0m	81.6%	no data
0.064%	State Street Global Advisors, Inc.	116,824	₩247.1m	-3.9%	no data
0.045%	Norges Bank Investment Management	82,942	₩175.4m	-87.3%	no data
0.016%	Hanwha Asset Management Co. Ltd.	29,791	₩63.0m	0%	no data
0.0076%	Yungjin Pharmaceutical Co., Ltd.,ESOP	13,883	₩29.4m	0%	no data
0.0057%	KB Asset Management Co., Ltd.	10,416	₩22.0m	-75.6%	no data
0.00046%	American Century Investment Management Inc	848	₩1.8m	0%	no data
0.00038%	NH-Amundi Asset Management	688	₩1.5m	7.33%	no data
0.00034%	Korea Investment Management Co., Ltd.	615	₩1.3m	-52.4%	no data
0.00032%	Invesco Capital Management LLC	578	₩1.2m	0%	no data
0.00012%	Consus Asset Management Co. Ltd.	218	₩464.2k	0%	0.01%